The US Food and Drug Administration likely will need a risk-based approach to reviewing the artificial intelligence aspects of drug applications as the technology becomes more pervasive in regulatory submissions, Center for Drug Evaluation and Research Director Patrizia Cavazzoni said at the BIO 2024 FDA town hall.
As the use of AI in applications increases it will become both economically unrealistic and infeasible from a time perspective...







